Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Ulcerative Colitis | Research article

Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study

Authors: Ayumi Ito, Syun Murasugi, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Tacrolimus (TAC) is a powerful remission-inducing drug for refractory ulcerative colitis (UC). However, it is unclear whether mucosal healing (MH) influences relapse after completion of TAC.We investigated whether MH is related to relapse after TAC.
Patients: Among 109 patients treated with TAC, 86 patients achieved clinical remission and 55 of them underwent colonoscopy at the end of TAC. These 55 patients were investigated.

Methods

Patients with MH at the end of TAC were classified into the MH group (n = 41), while patients without MH were classified into the non-MH group (n = 14). These groups were compared with respect to 1) clinical characteristics before treatment, 2) clinical characteristics on completion of treatment, and 3) the relapse rate and adverse events rates. This is a retrospective study conducted at a single institution.

Results

1) There was a significant difference in baseline age between the two groups before TAC therapy, but there were no significant differences in other clinical characteristics. The NMH group was younger (MH group: 48.1 (23–79) years, NMH group: 36.3 (18–58) years, P = 0.007). Endoscopic scores showed significant differences between the 2 groups at the end of TAC. There were also significant differences in the steroid-free rate after 24 weeks (MH group: 85.3%, NMH group 50%, P = 0.012). There was no significant difference in the relapse rate between the 2 groups at 100 days after remission, but a significant difference was noted at 300 days (17% vs. 43%), 500 days (17% vs. 75%), and 1000 days (17% vs. 81%) (all P < 0.05).

Conclusions

TAC is effective for refractory ulcerative colitis. However, even if clinical remission is achieved, relapse is frequent when colonoscopy shows that MH has not been achieved. It is important to evaluate the mucosal response by colonoscopy on completion of TAC.
Literature
1.
go back to reference Ungaro R, Mehandru S, Colombel JF. Ulcerative colitis. Lancet. 2017;29(389):1756–70.CrossRef Ungaro R, Mehandru S, Colombel JF. Ulcerative colitis. Lancet. 2017;29(389):1756–70.CrossRef
2.
go back to reference Harbord M, Eliakim R, Carbonnel F, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn's Colitis. 2017;11:769–84.CrossRef Harbord M, Eliakim R, Carbonnel F, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn's Colitis. 2017;11:769–84.CrossRef
3.
go back to reference Randall J, Singh B, George BD, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404–9.CrossRef Randall J, Singh B, George BD, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404–9.CrossRef
4.
go back to reference Øresland T, Bemelman WA, D'Hoore A, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn's Colitis. 2015;9:4–25.CrossRef Øresland T, Bemelman WA, D'Hoore A, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn's Colitis. 2015;9:4–25.CrossRef
5.
go back to reference Ogata H, Nakamura M, Hibi T, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255–62.CrossRef Ogata H, Nakamura M, Hibi T, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255–62.CrossRef
6.
go back to reference Komaki Y, Komaki F, Sakuraba A, et al. A efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J Crohn's Colitis. 2016;10:484–94.CrossRef Komaki Y, Komaki F, Sakuraba A, et al. A efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J Crohn's Colitis. 2016;10:484–94.CrossRef
7.
go back to reference Frøslie KF, Jahnsen J, Vatn MH, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.CrossRef Frøslie KF, Jahnsen J, Vatn MH, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.CrossRef
8.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRef
9.
go back to reference Travis SP, Schnell D, Sandborn WJ, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987–95.CrossRef Travis SP, Schnell D, Sandborn WJ, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987–95.CrossRef
10.
go back to reference Lichtiger S, Present DH, Hanauer S, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.CrossRef Lichtiger S, Present DH, Hanauer S, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.CrossRef
12.
go back to reference Colombel JF, Rutgeerts P, Sandborn WJ, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.CrossRef Colombel JF, Rutgeerts P, Sandborn WJ, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.CrossRef
13.
go back to reference Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–70.CrossRef Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–70.CrossRef
14.
go back to reference Testa A, Castiglione F, Colombo GL, et al. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 2017;22:297–303.CrossRef Testa A, Castiglione F, Colombo GL, et al. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 2017;22:297–303.CrossRef
15.
go back to reference Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:9–14.CrossRef Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:9–14.CrossRef
16.
go back to reference Faubion WA Jr, Loftus EV Jr, Sandborn WJ, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.CrossRef Faubion WA Jr, Loftus EV Jr, Sandborn WJ, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.CrossRef
17.
go back to reference Khan N, Abbas A, Balart L, et al. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963–9.CrossRef Khan N, Abbas A, Balart L, et al. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963–9.CrossRef
18.
go back to reference Khan NH, Almukhtar RM, Abbas AM, et al. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long term course of the disease – a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374–81.CrossRef Khan NH, Almukhtar RM, Abbas AM, et al. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long term course of the disease – a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374–81.CrossRef
19.
go back to reference Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33:289–94.CrossRef Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33:289–94.CrossRef
20.
go back to reference Eugene C. Ulcerative colitis practice guidelines in adults. Clin Res Hepatol Gastroenterol. 2012;36:107–9.CrossRef Eugene C. Ulcerative colitis practice guidelines in adults. Clin Res Hepatol Gastroenterol. 2012;36:107–9.CrossRef
21.
go back to reference Miyoshi J, Iwao Y, Hibi T, et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013 Dec;7(12):609–14.CrossRef Miyoshi J, Iwao Y, Hibi T, et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013 Dec;7(12):609–14.CrossRef
22.
go back to reference Guthrie E, Jackson J, Creed F, et al. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol. 2002;97:1994–9.CrossRef Guthrie E, Jackson J, Creed F, et al. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol. 2002;97:1994–9.CrossRef
23.
go back to reference Leong RW, Lee YT, Sung JJ, et al. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the inflammatory bowel disease questionnaire. Aliment Pharmacol Ther. 2003;17:711–8.CrossRef Leong RW, Lee YT, Sung JJ, et al. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the inflammatory bowel disease questionnaire. Aliment Pharmacol Ther. 2003;17:711–8.CrossRef
24.
go back to reference Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplantation. 2008;22(1):1–15. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplantation. 2008;22(1):1–15.
25.
go back to reference Baumgart DC, Pintoffl JP, Dignass AU, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease a long-term follow-up. Am J Gastroenterol. 2006;101:1048–56.CrossRef Baumgart DC, Pintoffl JP, Dignass AU, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease a long-term follow-up. Am J Gastroenterol. 2006;101:1048–56.CrossRef
Metadata
Title
Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study
Authors
Ayumi Ito
Syun Murasugi
Teppei Omori
Shinichi Nakamura
Katsutoshi Tokushige
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01317-9

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.